Cardiff Oncology sues Nerviano Medical Sciences over onvansertib license inventorship dispute

Cardiff Oncology, Inc.

Filed suit in SD California for injunctive relief and declaratory judgment it did not breach license agreement for onvansertib.
Dispute stems from NMS allegation that Cardiff failed to name an NMS employee as joint inventor on U.S. Patent Nos. 12,144,813 and 12,263,173.
Cardiff maintains no breach occurred; agreement does not require naming NMS employees on inventions made solely by Cardiff.
NMS sent written notice of alleged material breach on February 24, 2026, as previously disclosed.
Judicial intervention sought after prior discussions failed to resolve the disagreement.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.